Risk of vigabatrin‐associated brain abnormalities on <scp>MRI</scp> in the treatment of infantile spasms is dose‐dependent

Abstract

We have demonstrated dose-dependent risk of asymptomatic VABAM and uncovered a possible association between symptomatic VABAM and concomitant hormonal therapy. Caution should be exercised in the use of high VGB dosage (i.e., >175 mg/kg/day), and further study is warranted to confirm the potential impact of hormonal therapy.